Catalyst Wire Dossier Catalyst Wire Dossier

APL-1202

APL-1202 · Jiangsu Yahong Meditech Co., Ltd (Asieris)
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for APL-1202, covering 2020-07-20 to 2022-02-22. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients [Phase 3]

See pricing